Boudewijn, Ilse M. http://orcid.org/0000-0003-0438-696X
Faiz, Alen
Steiling, Katrina
van der Wiel, Erica
Telenga, Eef D.
Hoonhorst, Susan J. M.
ten Hacken, Nick H. T.
Brandsma, Corry-Anke
Kerstjens, Huib A. M.
Timens, Wim
Heijink, Irene H.
Jonker, Marnix R.
de Bruin, Harold G.
Sebastiaan Vroegop, J.
Pasma, Henk R.
Boersma, Wim G.
Wielders, Pascal
van den Elshout, Frank
Mansour, Khaled
Spira, Avrum
Lenburg, Marc E.
Guryev, Victor
Postma, Dirkje S.
van den Berge, Maarten
Funding for this research was provided by:
Chiesi Farmaceutici
Koninklijke Nederlandse Akademie van Wetenschappen
Stichting Astma Bestrijding
Top Institute Pharma
Rijksuniversiteit Groningen
University Medical Center Utrecht
Nycomed BV
GlaxoSmithKline
National Institutes of Health (NIH/NHLBI 1R01 HL095388, KL2RR025770)
Center for Integration of Medicine and Innovative Technology (CIMIT Young Clinician Research Award)
RESPIRE2 fellowship (PCOFUNDGA-2012-600368)
Article History
Received: 30 August 2017
Accepted: 11 December 2017
First Online: 21 December 2017
Ethics approval and consent to participate
: Identification cohort: The ethical committee of the University Medical Center Groningen (Medisch Ethische Toetsingscommisie) approved the study and all included subjects gave their written informed consent.Comparator cohort 1: Institutional review board approval was obtained from the participating institutions and all subject gave their written informed consent.Comparator cohort 2: The ethical committee of the University Medical Center Groningen approved the study and all included subjects gave their written informed consent.
: Not applicable.
: MvdB reports research grants paid to the University from Chiesi, GlaxoSmithKline, TEVA and AstraZeneca. HAMK reports fees paid to the University for consultancies/advisory boards and fees per patient for recruitment from GlaxoSmithKline, Boehringer Ingelheim and Novartis. WT reports fees paid to the University from Pfizer, GlaxoSmithKline, Chiesi, Roche Diagnostics/Ventana, Biotest, Merck Sharp Dohme, Novartis, Lilly Oncology and a grant from the Dutch Asthma Fund. PW reports personal fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and a grant from GlaxoSmithKline. MEL reports grants from NIH/NHLBI during the conduct of the study; in addition, MEL has a patent US PTO 14/406,607 pending. DSP reports consultancy fees or research grants paid to the University from Astra Zeneca, Chiesi, Genentec, GlaxoSmithKline, Roche, TEVA, Takeda and Boehringer Ingelheim. KS has a patent pending for the Boston University: “Biomarkers of COPD disease activity”. IMB, AF, EvdW, EDT, SJMH, NHTtH, CAB, IHH, MRJ, HGdB, JSV, HRP, WB, FvdE, KM, AS and VG have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.